Objectively measured physical activity as a COPD clinical trial outcome

Burtin, Chris, Mohan, Divya, Troosters, Thierry, Watz, Henrik, Hopkinson, Nicholas S., Garcia-Aymerich, Judith, Moy, Marilyn L., Vogiatzis, Ioannis, Rossiter, Harry B., Singh, Sally, Merrill, Debora D., Hamilton, Alan, Rennard, Stephen I., Fageras, Malin, Petruzzelli, Stefano, Tal-Singer, Ruth, Tomaszewski, Erin, Corriol-Rohou, Solange, Rochester, Carolyn L., Sciurba, Frank C., Casaburi, Richard, D-C Man, William, Van Lummel, Rob C., Cooper, Christopher B., Demeyer, Heleen, Spruit, Martijn A. and Vaes, Anouk (2021) Objectively measured physical activity as a COPD clinical trial outcome. Chest, 160 (6). pp. 2080-2100. ISSN 0012-3692

Burtin SR physical activity as clinical trial outcome - Chest.pdf - Accepted Version
Available under License Creative Commons Attribution Non-commercial No Derivatives 4.0.

Download (519kB) | Preview
Official URL: https://doi.org/10.1016/j.chest.2021.06.044


Reduced physical activity is common in COPD and is associated with poor outcomes. Physical activity is therefore a worthy target for intervention in clinical trials, however, trials evaluating physical activity have used heterogeneous methodologies.

Research question
What is the available evidence on the efficacy and/or effectiveness of various interventions to enhance objectively measured physical activity in patients with COPD, taking into account minimal preferred methodological quality of physical activity assessment? Study design and Methods In this narrative review, the COPD Biomarker Qualification Consortium (CBQC) task force searched three scientific databases for articles that reported the effect of an intervention on objectively-measured physical activity in COPD. Based on scientific literature and expert consensus, only studies with ≥7 measurement days and ≥4 valid days of ≥8 hours of monitoring were included in the primary analysis.

37 of 110 (34%) identified studies fulfilled the criteria, investigating the efficacy and/or effectiveness of physical activity behavior change programs (n=7), mobile health or eHealth interventions (n=9), rehabilitative exercise (n=9), bronchodilation (n=6), lung volume reduction procedures (n=3) and other interventions (n=3). Results are generally variable, reflecting the large variation in study characteristics and outcomes. Few studies show an increase beyond the proposed minimal important change of 600-1100 daily steps, indicating that enhancing physical activity levels is a challenge.

Only a third of clinical trials measuring objective physical activity in people with COPD fulfilled the pre-set criteria regarding physical activity assessment. Studies showed variable effects on physical activity even when investigating similar interventions.

Item Type: Article
Additional Information: Funding information: Funding for the COPD Biomarkers Qualification Consortium Working Group was provided by AstraZeneca, Boehringer Ingelheim, GSK and Chiesi. This work was presented as a thematic poster at the European Respiratory Society Congress in Madrid 2019.
Subjects: B100 Anatomy, Physiology and Pathology
C600 Sports Science
C900 Others in Biological Sciences
Department: Faculties > Health and Life Sciences > Sport, Exercise and Rehabilitation
Depositing User: Rachel Branson
Date Deposited: 05 Jul 2021 14:30
Last Modified: 01 Jul 2022 03:31
URI: http://nrl.northumbria.ac.uk/id/eprint/46605

Actions (login required)

View Item View Item


Downloads per month over past year

View more statistics